Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$4.06 +2.5%	$3.91	$2.60 ▼ $7.77	$224.80M	1.58	89,822 shs	77,760 shs
LENZ LENZ Therapeutics	$30.48 +3.9%	$31.07	$16.53 ▼ $38.93	$836.55M	0.42	367,756 shs	703,905 shs
SNDX Syndax Pharmaceuticals	$12.57 +21.1%	$9.95	$8.58 ▼ $22.50	$893.17M	0.74	1.90 million shs	9.12 million shs
TRVI Trevi Therapeutics	$7.41 -1.1%	$6.52	$2.36 ▼ $8.11	$878.52M	0.58	1.84 million shs	1.02 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	+2.53%	+2.01%	+7.69%	+22.96%	-12.88%
LENZ LENZ Therapeutics	+3.92%	-3.76%	-6.32%	+20.28%	+36.80%
SNDX Syndax Pharmaceuticals	+21.10%	+21.45%	+35.51%	+25.83%	-36.06%
TRVI Trevi Therapeutics	-1.07%	-1.85%	+25.68%	+11.26%	+183.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.325 of 5 stars	1.0	1.0	0.0	0.0	2.5	0.6
LENZ LENZ Therapeutics	1.6984 of 5 stars	3.6	0.0	0.0	3.7	0.8	0.0
SNDX Syndax Pharmaceuticals	3.6913 of 5 stars	3.5	1.0	4.4	3.8	0.8	0.0
TRVI Trevi Therapeutics	3.0083 of 5 stars	4.7	1.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	0.00	N/A	N/A	N/A
LENZ LENZ Therapeutics	3.17	Buy	$49.60	62.73% Upside
SNDX Syndax Pharmaceuticals	2.91	Moderate Buy	$36.91	193.63% Upside
TRVI Trevi Therapeutics	3.30	Buy	$20.88	181.71% Upside

Current Analyst Ratings Breakdown

Latest DSGN, LENZ, TRVI, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	SNDX Syndax Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $51.00
8/5/2025	SNDX Syndax Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $56.00
7/31/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $49.00
7/31/2025	LENZ LENZ Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
7/28/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $48.00
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00

(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.24 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	45.68	N/A	N/A	$3.38 per share	3.72
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	N/A
LENZ LENZ Therapeutics	-$49.77M	-$1.90	N/A	N/A	N/A	N/A	-25.63%	-24.43%	8/13/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-428.48%	-115.57%	-56.10%	N/A
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-58.41%	-52.52%	8/7/2025 (Estimated)

Latest DSGN, LENZ, TRVI, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million
7/30/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.58	-$0.53	+$0.05	-$0.53	$5.00 million	$5.00 million
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	28.37	28.37
LENZ LENZ Therapeutics	N/A	20.54	20.54
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
LENZ LENZ Therapeutics	54.32%
SNDX Syndax Pharmaceuticals	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
LENZ LENZ Therapeutics	6.90%
SNDX Syndax Pharmaceuticals	4.10%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
LENZ LENZ Therapeutics	110	28.52 million	26.55 million	N/A
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

DSGN, LENZ, TRVI, and SNDX Headlines

Recent News About These Companies

41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbH

August 4 at 8:32 AM | marketbeat.com

Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 6,352.7%

August 3 at 3:53 AM | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 6,352.7% in July

August 2, 2025 | marketbeat.com

Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Thursday

August 2, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 0.1% - Here's What Happened

August 1, 2025 | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

July 31, 2025 | prnewswire.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 29, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Time to Buy?

July 24, 2025 | marketbeat.com

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

July 11, 2025 | zacks.com

Trevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

July 2, 2025 | msn.com

TRVI Trevi Therapeutics, Inc. - Seeking Alpha

July 1, 2025 | seekingalpha.com

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

July 1, 2025 | prnewswire.com

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm

June 26, 2025 | globenewswire.com

TRVI - Trevi Therapeutics Inc Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, LENZ, TRVI, and SNDX Company Descriptions

Design Therapeutics NASDAQ:DSGN

$4.06 +0.10 (+2.53%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$5.33 +1.27 (+31.28%)

As of 04:00 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

LENZ Therapeutics NASDAQ:LENZ

$30.48 +1.15 (+3.92%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$30.90 +0.42 (+1.38%)

As of 04:04 AM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Syndax Pharmaceuticals NASDAQ:SNDX

$12.57 +2.19 (+21.10%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$12.58 +0.01 (+0.08%)

As of 04:15 AM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Trevi Therapeutics NASDAQ:TRVI

$7.41 -0.08 (-1.07%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$3.51 -3.90 (-52.63%)

As of 04:00 AM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time